Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Lett. 2018 Oct 9;440-441:1–10. doi: 10.1016/j.canlet.2018.10.003

Figure 3. Pan-PIM kinase inhibitor and lenalidomide combination resulted in more effective anti-myeloma activity in vivo in systemic xenograft myeloma model.

Figure 3.

MM1R cells stably expressing luciferase (1.5×106 cells/mouse) were injected via tail vein into sublethally irradiated (1.75Gy) NSG mice. Tumor growth was followed weekly by bioluminescence imaging. At day 19 of cell injection, mice were treated (indicated as Week 0 in A) with either: DMSO, SGI1776 (35mg/kg body weight), lenalidomide (25mg/kg body weight), or the combination of SGI1776 and lenalidomide by daily oral gavage. A. Tumor growth was significantly reduced in mice treated with a combination of SGI1776 and lenalidomide. B. Combination of SGI1776 and lenalidomide significantly prolonged animal survival. C. No added hematologic or hepatic toxicities were observed in SGI1776 and lenalidomide combination treatment. Liver alanine transaminase (ALT) activity was measured by colorimetric ELISA. (ns: no statistically significant; *: p<0.05; **: p< 0.01)